Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Nivolumab and ipilimumab for metastatic sarcoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.17
Views: 3150

Dr Sandra D'Angelo - Memorial Sloan Kettering Cancer Center, New York, USA

Dr D'Angelo speaks with ecancer at ASCO 2017 about results from a phase II multicenter trial of nivolumab with or without ipilimumab for patients with metastatic sarcoma.

She notes the success of those responding to treatment, with a manageable toxicity profile, and considers how response rates could be improved considering the frequency of treatment related adverse events.

Nivolumab and ipilimumab have also been trialled in combination to treat advanced skin cancer, as discussed by Dr James Larkin at AACR 2017.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation